Neoadjuvant intra-arterial chemoembolization improves tumor pathological regression and survival in Borrmann type IV gastric cancer

doi:10.5306/wjco.123351

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

(1)

(0)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. Aug 24, 2026; 17(8): 123351
Published online Aug 24, 2026. doi: 10.5306/wjco.123351

Table 1 Comparison of patients’ clinical characteristics between before and after intra-arterial chemoembolization

Characteristics	Pre-IAC	Post-IAC	P value
Age (years)	66.0 (52.8-70.0)
Sex
Male	51 (72.9)
Female	19 (27.1)
ECOG PS
0	60 (85.7)
1	10 (14.3)
BMI (kg/m²)	21.8 ± 3.4	21.9 ± 3.5	0.712
Smoking	38 (54.3)
Drinking	35 (50.0)
Hypertension	14 (20.0)
T2DM	9 (12.9)
Hemoglobin (g/L)	113.6 ± 28.3	104.6 ± 25.5	P < 0.05^a
Albumin (g/L)	37.9 ± 4.3	36.2 ± 5.0	P < 0.05^a
CEA (ng/mL)	2.2 (1.3-4.8)	3.1 (2.1-5.0)	P < 0.05^a
CA 19-9 (U/mL)	9.1 (6.6-15.8)	9.5 (6.7-14.4)	0.089
Tumor location
Fundus	23 (32.9)
Body	24 (34.3)
Antrum	18 (25.7)
Whole stomach	5 (7.1)
Degree of differentiation
Poor	49 (70)
Well	21 (30)
Tumor stage			P < 0.05^a
cT3	18 (25.7)	19 (27.1)
cT4a	36 (51.4)	41 (58.6)
cT4b	16 (22.9)	10 (14.3)
Node stage			P < 0.05^a
cN0	8 (11.4)	11 (15.7)
cN1	14 (20.0)	28 (40.0)
cN2	31 (44.3)	25 (35.7)
cN3	17 (24.3)	6 (8.6)
TNM stage			P < 0.05^a
IIa	6 (8.6)	8 (11.4)
IIb	4 (5.7)	14 (20.0)
IIIa	29 (41.4)	31 (44.3)
IIIb	19 (27.1)	13 (18.6)
IIIc	12 (17.1)	4 (5.7)
IAC regimen
DOS	23 (32.9)
Nab-P-SOX	47 (67.1)
Number of IAC
1	48 (68.6)
≥ 2	22 (31.4)

^aP < 0.05.

Continuous variables are expressed as mean ± SD if normally distributed, or median and interquartile range if non-normally distributed; categorical variables as n (%). IAC: Intra-arterial chemoembolization; ECOG PS: Eastern Cooperative Oncology Group performance status; BMI: Body mass index; T2DM: Type 2 diabetes mellitus; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; TNM: Tumor-node-metastasis; DOS: Docetaxel, oxaliplatin, and S-1; Nab-P-SOX: Nanoparticle albumin-bound paclitaxel, oxaliplatin, and S-1.

Full Size Table

Citation: Wu XX, Yang HD, Min J, Yuan C, Li LS, Zhang W, Tong Y. Neoadjuvant intra-arterial chemoembolization improves tumor pathological regression and survival in Borrmann type IV gastric cancer. World J Clin Oncol 2026; 17(8): 123351
URL: https://www.wjgnet.com/2218-4333/full/v17/i8/123351.htm
DOI: https://dx.doi.org/10.5306/wjco.123351

Wu XX, Yang HD, Min J, Yuan C, Li LS, Zhang W, Tong Y. Neoadjuvant intra-arterial chemoembolization improves tumor pathological regression and survival in Borrmann type IV gastric cancer. World J Clin Oncol 2026; 17(8): 123351 [DOI: 10.5306/wjco.123351]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.